BioAtla will receive an initial $5 million for general operating and Phase 3 clinical trial expenses to advance Oz-V in 2L+ ...
Naltrexone has long been used to treat alcohol use disorder. Now it’s gaining attention as a tool for people who want to cut ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback